620 related articles for article (PubMed ID: 28836985)
1. Providing guidance for genomics-based cancer treatment decisions: insights from stakeholder engagement for post-prostatectomy radiation therapy.
Abe J; Lobo JM; Trifiletti DM; Showalter TN
BMC Med Inform Decis Mak; 2017 Aug; 17(1):128. PubMed ID: 28836985
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.
Lobo JM; Dicker AP; Buerki C; Daviconi E; Karnes RJ; Jenkins RB; Patel N; Den RB; Showalter TN
PLoS One; 2015; 10(3):e0116866. PubMed ID: 25837660
[TBL] [Abstract][Full Text] [Related]
4. Reconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era.
Lobo JM; Stukenborg GJ; Trifiletti DM; Patel N; Showalter TN
J Comp Eff Res; 2016 Jul; 5(4):375-82. PubMed ID: 27294829
[TBL] [Abstract][Full Text] [Related]
5. A personalized decision aid for prostate cancer shared decision making.
Bagshaw HP; Martinez A; Heidari N; Scheinker D; Pollack A; Stoyanova R; Horwitz E; Morton G; Kishan AU; Buyyounouski MK
BMC Med Inform Decis Mak; 2021 Dec; 21(1):374. PubMed ID: 34972513
[TBL] [Abstract][Full Text] [Related]
6. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.
Michalopoulos SN; Kella N; Payne R; Yohannes P; Singh A; Hettinger C; Yousefi K; Hornberger J;
Curr Med Res Opin; 2014 Aug; 30(8):1547-56. PubMed ID: 24803160
[TBL] [Abstract][Full Text] [Related]
7. Prostatectomy versus radiotherapy for early-stage prostate cancer (PREPaRE) study: protocol for a mixed-methods study of treatment decision-making in men with localised prostate cancer.
Smith AB; Mancuso P; Sidhom M; Wong K; Berry M; Rincones O; Forstner D; Bokey L; Girgis A
BMJ Open; 2017 Nov; 7(11):e018403. PubMed ID: 29102996
[TBL] [Abstract][Full Text] [Related]
8. The "Begin Exploring Fertility Options, Risks and Expectations" (BEFORE) decision aid: development and alpha testing of a fertility tool for premenopausal breast cancer patients.
Speller B; Metcalfe K; Kennedy ED; Facey M; Greenblatt E; Scheer AS; Warner E; Joy AA; Wright FC; Baxter NN
BMC Med Inform Decis Mak; 2019 Oct; 19(1):203. PubMed ID: 31660965
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.
Thompson IM; Valicenti RK; Albertsen P; Davis BJ; Goldenberg SL; Hahn C; Klein E; Michalski J; Roach M; Sartor O; Wolf JS; Faraday MM
J Urol; 2013 Aug; 190(2):441-9. PubMed ID: 23707439
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant vs. salvage Radiation Therapy after Radical Prostatectomy: Role of Decipher® in the Era of Personalized Medicine.
Nowroozi A; Karimi A; Alilou S; Amini E
Urol J; 2021 Jan; 18(3):349-350. PubMed ID: 33423246
[TBL] [Abstract][Full Text] [Related]
11. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.
van Tol-Geerdink JJ; Willem Leer J; Weijerman PC; van Oort IM; Vergunst H; van Lin EN; Alfred Witjes J; Stalmeier PF
BJU Int; 2013 Apr; 111(4):564-73. PubMed ID: 22882966
[TBL] [Abstract][Full Text] [Related]
12. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
13. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
14. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
15. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
Reed SD; Stewart SB; Scales CD; Moul JW
Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
[TBL] [Abstract][Full Text] [Related]
16. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.
Badani KK; Thompson DJ; Brown G; Holmes D; Kella N; Albala D; Singh A; Buerki C; Davicioni E; Hornberger J
BJU Int; 2015 Mar; 115(3):419-29. PubMed ID: 24784420
[TBL] [Abstract][Full Text] [Related]
17. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
18. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
Parikh R; Sher DJ
Cancer; 2012 Jan; 118(1):258-67. PubMed ID: 21720990
[TBL] [Abstract][Full Text] [Related]
19. User-centered design and the development of patient decision aids: protocol for a systematic review.
Witteman HO; Dansokho SC; Colquhoun H; Coulter A; Dugas M; Fagerlin A; Giguere AM; Glouberman S; Haslett L; Hoffman A; Ivers N; Légaré F; Légaré J; Levin C; Lopez K; Montori VM; Provencher T; Renaud JS; Sparling K; Stacey D; Vaisson G; Volk RJ; Witteman W
Syst Rev; 2015 Jan; 4(1):11. PubMed ID: 25623074
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients.
Knight SJ; Nathan DP; Siston AK; Kattan MW; Elstein AS; Collela KM; Wolf MS; Slimack NS; Bennett CL; Golub RM
Clin Prostate Cancer; 2002 Sep; 1(2):105-14. PubMed ID: 15046701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
